Inactief instrument

Andere talen MEDIGENE NA Swiss Exchange

Aandelen

OXMDGG

DE0005020903

slotkoers Swiss Exchange Andere beurzen
- ^EUR	-

21/05	Medigene, BioNTech verlengen samenwerking kankerimmunotherapie	MT
21/05	Medigene AG's wereldwijde onderzoeks- en samenwerkingsovereenkomst met BioNTech SE wordt verlengd na de oorspronkelijk aangekondigde termijn	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Medigene, BioNTech Extend Cancer Immunotherapy Partnership	21/05
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	21/05
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05
Medigene Ag Maintains Earnings Guidance for 2024	14/05
Medigene Boosts Share Capital Via Rights Offering, Private Placement	08/05
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	02/05
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	02/05
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	25/04
Rights Issue: 1 new share @ 1.2 EUR for 5 existing shares	24/04	FA
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	08/04
Medigene Gets European Patent for T-Cell Receptor Technology	04/04
Medigene AG Secures European Patent for Its iM-TCR Technology	04/04
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	28/03
Medigene Ag Provides Earnings Guidance for 2024	28/03
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	04/03
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	12/02
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	21/11
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	04/11
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MEDIGENE NA Swiss Exchange

Aandelen

OXMDGG

DE0005020903

Andere talen

Filters